Login / Signup

Improved anti-breast cancer activity by doxorubicin-loaded super stealth liposomes.

Donatella PaolinoNicola d'AvanzoElena CanatoLuigi CirioloAntonella GrigolettoMaria Chiara CristianoAntonia MancusoChristian CeliaGianfranco PasutMassimo Fresta
Published in: Biomaterials science (2024)
PEGylation is currently used for the synthesis of stealth liposomes and to enhance the pharmacokinetic and biopharmaceutical properties of payloads. PEGylated dendron phospholipids can decrease the detachment of polyethylene glycol (PEG) from the liposomal surface owing to an increased hydrophobic anchoring effect on the phospholipid bilayer of liposomes and thus generating super stealth liposomes that are suitable for the systemic delivery of anticancer drugs. Herein, doxorubicin hydrochloride-loaded super stealth liposomes were studied for the treatment of breast cancer lung metastasis in an animal model. The results demonstrated that the super stealth liposomes had suitable physicochemical properties for in vivo administration and could significantly increase the efficacy of doxorubicin in breast cancer lung metastasis tumor-bearing mice compared to the free drug. The super stealth liposomes also increased doxorubicin accumulation inside the tumor tissue. The permanence of PEG on the surface of the super stealth liposomes favored the formation of a depot of therapeutic nanocarriers inside the tumor tissue by improving their permanence after stopping treatment. The doxorubicin-loaded super stealth liposomes increased the survival of the mouse tumor model. These promising results demonstrate that the doxorubicin-loaded super stealth liposomes could be an effective nanomedicine to treat metastatic breast cancer.
Keyphrases
  • drug delivery
  • cancer therapy
  • drug release
  • metastatic breast cancer
  • adipose tissue
  • fatty acid
  • drug induced
  • combination therapy
  • breast cancer risk